TY - JOUR
T1 - ADRB2 G-G haplotype associated with breast cancer risk among Hispanic and non-Hispanic white women
T2 - Interaction with type 2 diabetes and obesity
AU - Connor, Avonne
AU - Baumgartner, Richard N.
AU - Kerber, Richard A.
AU - O'Brien, Elizabeth
AU - Rai, Shesh N.
AU - Wolff, Roger K.
AU - Slattery, Martha L.
AU - Giuliano, Anna R.
AU - Risendal, Betsy C.
AU - Byers, Tim E.
AU - Baumgartner, Kathy B.
N1 - Funding Information:
Acknowledgments This study was funded by grants: CA 078682, CA 078762, CA 078552, CA 078802, and R01CA140002. This research also was supported by the Utah Cancer Registry, which is funded by Contract #N01-PC-67000 from the National Cancer Institute, with additional support from the State of Utah Department of Health, the New Mexico Tumor Registry, and the Arizona and Colorado cancer registries, funded by the Centers for Disease Control and Prevention National Program of Cancer Registries and additional state support. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute. This study was completed and also funded under the Susan G. Komen Breast Cancer Disparities Epidemiology Research Training Program: University of Louisville (Grant #KG09092). We would also like to acknowledge the contributions of Sandra Edwards, Roger Edwards, Stephanie Denkhoff, Erica Wolff, and Michael Hoffman.
PY - 2012/10
Y1 - 2012/10
N2 - Introduction Polymorphisms in the beta-2-adrenergic receptor (ADRB2) gene have been studied in relation to risk of type 2 diabetes and obesity, risk factors that have received increased attention in relation to breast cancer. We evaluated the hypothesis that ADRB2 variants (rs1042713, rs1042714) are associated with breast cancer risk in non- Hispanic white (NHW) and Hispanic (H) women using data from a population-based case-control study conducted in the southwestern United States. Methods Data on lifestyle and medical history, and blood samples, were collected during in-person interviews for incident primary breast cancer cases (1,244 NHW, 606 H) and controls (1,330 NHW, 728 H). ADRB2 genotypes for rs1042713(G/A) and rs1042714(G/C) were determined using TaqMan assays. The associations of each variant and corresponding haplotypes with breast cancer were estimated using multivariable logistic regression. Results Two copies compared to one or zero copies of the ADRB2 G-G haplotype were associated with increased breast cancer risk for NHW women [odds ratio (OR), 1.95; 95 % confidence interval (95 % CI), 1.26-3.01], but with reduced risk for H women [OR, 0.74; 95 % CI, 0.50-1.09]. Effect estimates were strengthened for women with a body mass index (BMI) ≥25 kg/m2 [H: OR, 0.50; 95 % CI, 0.31-0.82; NHW: OR, 3.85; 95 % CI, 1.88-7.88] and for H women with a history of diabetes [H: OR, 0.32; 95 % CI, 0.12-0.89]. Conclusions These data suggest that ethnicity modifies the association between the ADRB2 G-G haplotype and breast cancer risk, and being overweight or obese enhances the divergence of risk between H and NHW women.
AB - Introduction Polymorphisms in the beta-2-adrenergic receptor (ADRB2) gene have been studied in relation to risk of type 2 diabetes and obesity, risk factors that have received increased attention in relation to breast cancer. We evaluated the hypothesis that ADRB2 variants (rs1042713, rs1042714) are associated with breast cancer risk in non- Hispanic white (NHW) and Hispanic (H) women using data from a population-based case-control study conducted in the southwestern United States. Methods Data on lifestyle and medical history, and blood samples, were collected during in-person interviews for incident primary breast cancer cases (1,244 NHW, 606 H) and controls (1,330 NHW, 728 H). ADRB2 genotypes for rs1042713(G/A) and rs1042714(G/C) were determined using TaqMan assays. The associations of each variant and corresponding haplotypes with breast cancer were estimated using multivariable logistic regression. Results Two copies compared to one or zero copies of the ADRB2 G-G haplotype were associated with increased breast cancer risk for NHW women [odds ratio (OR), 1.95; 95 % confidence interval (95 % CI), 1.26-3.01], but with reduced risk for H women [OR, 0.74; 95 % CI, 0.50-1.09]. Effect estimates were strengthened for women with a body mass index (BMI) ≥25 kg/m2 [H: OR, 0.50; 95 % CI, 0.31-0.82; NHW: OR, 3.85; 95 % CI, 1.88-7.88] and for H women with a history of diabetes [H: OR, 0.32; 95 % CI, 0.12-0.89]. Conclusions These data suggest that ethnicity modifies the association between the ADRB2 G-G haplotype and breast cancer risk, and being overweight or obese enhances the divergence of risk between H and NHW women.
KW - Beta-2-adrenergic receptor
KW - Breast cancer
KW - Diabetes
KW - Haplotypes
KW - Hispanic
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=84866976362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866976362&partnerID=8YFLogxK
U2 - 10.1007/s10552-012-0043-6
DO - 10.1007/s10552-012-0043-6
M3 - Article
C2 - 22864926
AN - SCOPUS:84866976362
SN - 0957-5243
VL - 23
SP - 1653
EP - 1663
JO - Cancer Causes and Control
JF - Cancer Causes and Control
IS - 10
ER -